Administration ("FDA"); the outcome of further statistical analyses of the clinical data generated during the PREGNANT Study by the FDA; success in obtaining timely approval of PROCHIEVE in the new preterm birth indication by the FDA; the impact of competitive products and pricing; the timing and level of success of a future product launch; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations, including Medicaid; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; the ability to obtain and enforce patents and other intellectual property rights; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's and Watson's reports filed with the SEC, including, but not limited to, their respective Annual Reports on Form 10-K for the year ended December 31, 2010. Neither Columbia nor Watson undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.
PROCHIEVE® and CRINONE® are registered trademarks of Watson Pharmaceuticals, Inc.
ContactsFor Columbia Laboratories, Inc.
For Watson Pharmaceuticals, Inc. Investors
InvestorsLawrence A. Gyenes
Patty EisenhaurSVP, Chief Financial Officer & Treasurer
VP, Investor Relations and Corp. Comm. Columbia Laboratories, Inc.
(973) 355-8141(973) 486-8860--or--
Charlie MayrVP, The Trout Group LLC
SVP, Corporate Affairs(646) 378-2952
(973) 355-8483MediaAmy RaskopfPresident, Raskopf Communications, LLC(917) 673-5775Editors Note:A press conference sponsored by the Detroit Medical Center (DMC) and Wayne
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
|SOURCE Watson Pharmaceuticals, Inc.; Columbia Laboratories, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica2
. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient3
. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line4
. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets5
. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories6
. HealthWarehouse.com Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State7
. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO8
. Columbia Laboratories to Discuss Fourth Quarter and Year End 2010 Financial Results on March 10, 2011, Conference Call9
. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments10
. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)11
. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia